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ABSTRACT
Werner and Bloom syndromes are genetic RecQ
helicase disorders characterized by genomic instab-
ility. Biochemical and genetic data indicate that an
important protein interaction of WRN and Bloom syn-
drome (BLM) helicases is with the structure-specific
nuclease Flap Endonuclease 1 (FEN-1), an enzyme
that is implicated in the processing of DNA interme-
diates thatariseduringcellularDNAreplication, repair
and recombination. To acquire a better understand-
ing of the interaction of WRN and BLM with FEN-1, we
have mapped the FEN-1 binding site on the two RecQ
helicases. Both WRN and BLM bind to the extreme
C-terminal 18 amino acid tail of FEN-1 that is adjacent
to the PCNA binding site of FEN-1. The importance
of the WRN/BLM physical interaction with the FEN-1
C-terminal tail was confirmed by functional interac-
tion studies with catalytically active purified recom-
binant FEN-1 deletion mutant proteins that lack either
the WRN/BLM binding site or the PCNA interaction
site. The distinct binding sites of WRN and PCNA
and their combined effect on FEN-1 nuclease activity
suggest that they may coordinately act with FEN-1.
WRN was shown to facilitate FEN-1 binding to its
preferred double-flap substrate through its protein
interaction with the FEN-1 C-terminal binding site.
WRN retained its ability to physically bind and stimu-
late acetylated FEN-1 cleavage activity to the same
extent as unacetylated FEN-1. These studies provide
new insights to the interaction of WRN and BLM hel-
icases with FEN-1, and how these interactions might
be regulated with the PCNA–FEN-1 interaction during
DNA replication and repair.
INTRODUCTION
Werner syndrome (WS) is a rare genetic premature aging
disorder characterized by genomic instability (1). The replica-
tion (2–4) and recombination (5,6) defects of WS cells, as well
as their hypersensitivity to DNA damaging agents (7–10),
suggest that WRN processes genomic DNA structures that
arise at the elongating or stalled replication fork. Indeed,
the WRN protein has multiple DNA metabolic functions that
include DNA unwinding dependent on ATP hydrolysis
(11,12), 30–50 exonuclease activity (13–15) and strand anneal-
ing (16). A number of proteins involved in cellular DNA
metabolism physically and/or functionally interact with
WRN, supporting the notion that WRN participates in multiple
pathways by virtue of its intrinsic catalytic activities and
protein interactions [for review see (17,18)].
Of the numerous WRN protein interactions reported, we
have been particularly interested in the interaction of WRN
with Flap Endonuclease 1 (FEN-1) (19), a structure-specific
nuclease implicated in DNA replication, repair and recomb-
ination [for review see (20)]. Genetic and biochemical evid-
ence implicate FEN-1 in the process of Okazaki fragment
processing through its ability to cleave a double-flap DNA
substrate that arises during DNA synthesis strand displace-
ment. Yeast studies have also implicated FEN-1 in the main-
tenance of genomic stability, DNA damage response and
stabilization of telomeres. Mouse FEN-1 null blastocysts dis-
play proliferation failure and gamma radiation sensitivity (21).
FEN-1 haploinsufficiency in mice can lead to tumor progres-
sion (22), suggesting that FEN-1, like WRN, serves as a tumor
suppressor by its role in genome stability maintenance.
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Evidence for an in vivo function of the WRN-FEN-1 inter-
action in DNA replication was attained using a model yeast-
based system for genetic complementation analysis (23).
WRN was demonstrated to rescue the cellular phenotypes
of a dna2 mutant defective in a helicase–nuclease that parti-
cipates with FEN-1 in Okazaki fragment processing. Genetic
complementation studies indicated that human WRN rescues
dna2-1 mutant phenotypes of growth, cell cycle arrest and
sensitivity to the replication inhibitor hydroxyurea or DNA
damaging agent methylmethane sulfonate. Importantly,
expression of a conserved non-catalytic domain of WRN
that mediates the physical and functional interaction with
FEN-1 was sufficient to complement the dna2-1 mutant
phenotypes, suggesting a role of the conserved non-
catalytic domain of a RecQ helicase in DNA replication inter-
mediate processing.
In human cells, fluorescence resonance energy transfer
(FRET) analyses showed that WRN and FEN-1 form a com-
plex that co-localizes in foci associated with arrested replica-
tion forks (24). Biochemical analyses demonstrated that WRN
and FEN-1 together process branch-migrating DNA structures
associated with the replication fork (24). Molecular and cel-
lular evidence demonstrate that the Bloom syndrome helicase
(BLM) also interacts physically with FEN-1 and stimulates the
FEN-1 cleavage reaction through a region of the BLM C-
terminal domain that shares homology with the FEN-1 inter-
action domain of WRN (25). The physical and functional
interactions of the human RecQ helicases BLM and WRN
with FEN-1 are probable to be important for the roles of
these proteins in the maintenance of genome stability.
To gain further insight to how the FEN-1 cleavage reaction
is stimulated by WRN or BLM, we have performed mapping
studies to determine the interaction site on FEN-1. These
results indicate that WRN or BLM interacts with a site on
FEN-1 that is distinct from its other interacting partner PCNA.
FEN-1 can become acetylated in response to DNA damage,
causing a marked reduction in its cleavage activity (26). Acet-
ylated FEN-1 was stimulated by WRN, suggesting a potential
mechanism for modulating FEN-1 catalyzed DNA cleavage
during DNA replication and repair.
MATERIALS AND METHODS
Recombinant proteins
Recombinant His-tagged WRN protein was overexpressed
using a baculovirus/Sf9 insect system and purified as described
previously (24). Recombinant His-tagged WRN940–1432, over-
expressed in Escherichia coli, was purified as published (27).
Recombinant His-tagged FEN-1 (wild-type), FEN-1DP (resi-
dues 337–344 are deleted) or FEN-1DC (residues 360–380 are
deleted) were overexpressed in E.coli and purified as described
previously (28). Recombinant PCNA was kindly provided by
Dr Mark Kenny (Albert Einstein Cancer Center). Recombin-
ant His-tagged BLM protein was purified as described previ-
ously (29). Histone acetyltransferase p300 (p300-HAT) was
purchased from Active Motif.
GST–FEN-1–Sepharose affinity pull-down experiments
Details pertaining to the bacterial expression plasmids encod-
ing GST–FEN-1 recombinant protein fragments are found
in (30). GST–FEN-1 fusion proteins were overexpressed in
BL21(DE3) pLysS by 1 mM isopropyl-B-D-thiogalactopy-
ranoside induction for 8 h at 23C. The bacterial cell pellet
was lysed by sonication in Lysis buffer [phosphate-buffered
saline (PBS), 10% glycerol and 0.4% Triton X-100]. The
lysate was clarified by centrifugation at 35 000 r.p.m.
(Ti 60 rotor, Beckman) for 1 h at 4
C. Of the resulting super-
natant 1 ml was incubated with 100 ml of glutathione
S-transferase beads (50% v/v) for 1 h at 4C. The beads
were washed three times with 1 ml Lysis buffer, and split
into two aliquots, one for binding experiments and one for
determination of background signal in western blot analysis.
For binding experiments, protein-bound beads were incubated
for 1 h at 4C with 200 ng of purified recombinant WRN or
BLM proteins in 250 ml of Buffer D [50 mM HEPES (pH 7.1),
100 mM KCl and 10% glycerol]. The beads were subsequently
washed three times with 500 ml of Buffer D and eluted by
boiling treatment in 40 ml of Laemmli buffer [62.5 mM Tris–
HCl (pH 6.8), 2% sodium dodecyl sulfate, 25% glycerol, 5%
b-mercaptoethanol and 0.01% bromophenol blue]. Proteins
were electrophoresed on 8–16% gradient polyacrylamide
SDS gels and transferred onto PVDF membranes. Control
membranes were stained with amido black reagent to demon-
strate protein loading for samples. Membranes were probed
with rabbit polyclonal anti-WRN or anti-BLM antibodies
(1:250 and 1:500, respectively) followed by horseradish
peroxidase (HRP)-conjugated horse anti-rabbit secondary
antibody (1:5000; Santa Cruz Biotech) and ECL-Plus
(Amersham Pharmacia).
In vitro acetylation assays
Reactions (30 ml) contained 2 mg of purified recombinant
FEN-1, 0.1 mCi [14C]acetyl coenzyme A (Amersham
Pharmacia) and 100 ng p300-HAT in 50 mM Tris–HCl
(pH 8.0), 10% (v/v) glycerol, 150 mM NaCl, 1 mM DTT,
1 mM phenylmethylsulfonyl fluoride (PMSF) and 10 mM
sodium butyrate. Reactions were incubated at 30C for
30 min, and used for FEN-1 incision assays (described
below) and SDS–PAGE analysis on 10% polyacrylamide
gels. Gels were stained with Coomassie and subjected to
film autoradiography.
Subnuclear fractionation and immunoprecipitation
experiments
Hela cells were washed with cold PBS, resuspended in Lysis
buffer [50 mm Tris–HCl (pH 7.4), 150 mM NaCl, 5 mM
EDTA, 1% NP-40, 2 mM Na3VO4, 10 mM NaF, and 2 mg/
ml leupeptin, 1 mg/ml pepstatin, 1 mg/ml aprotinin and 1 mM
PMSF] for 30 min on ice and centrifuged at 15 000 g for 20 min
at 4C. The supernatant was recovered as total soluble fraction
and the pellet was washed once again with the Lysis buffer and
the insoluble chromatin was extracted with 0.5 M NaCl in the
Lysis buffer as the high salt fraction. The final chromatin pellet
was resuspended in Laemmli buffer and sonicated for 15 s in
Microson Ultrasonic Cell Disruptor. Each protein fraction,
corresponding to an equivalent cell number, was loaded for
10% SDS–PAGE and analyzed by immunoblotting with indic-
ated antibodies. For the preparation of chromatin fraction used
for the immunoprecipitation experiments, sequential subnuc-
lear fractionation from HeLa cells was based on the method of
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(31). In brief, cells were resuspended and permeabilized in low
salt buffer [10 mM HEPES (pH 7.4), 10 mM KCl and 50 mg/ml
digitonin] containing protease inhibitors (2 mg/ml leupeptin,
1 mg/ml pepstatin, 1 mg/ml aprotinin and 1 mM PMSF) and
1 mM Na3VO4 for 15 min at 4
C. Permeabilized nuclei were
recovered by centrifugation at 1000 g for 5 min at 4C fol-
lowed by two additional washes in the low salt buffer. The
nuclei were subsequently resuspended in low salt buffer and
incubated with 30 U of RNase-free DNase I (Roche Molecular
Biochemicals) for 15 min at 24C followed by an additional
15 min at 37C. Proteins from this DNase I-treated nuclei
fraction were solubilized by adding Extraction buffer [1%
Triton X-100, 50 mM HEPES (pH 7.4), 150 mM NaCl,
30 mM Na4P2O7·10H2O, 10 mM NaF and 1 mM EDTA]
containing protease and phosphatase inhibitors (see above)
and incubating for 10 min at 4C. The supernatant that was
collected from centrifugation (20 000 g, 10 min) was termed
the chromatin fraction. Protein (1 mg) from the chromatin
fraction was diluted 10-fold in Extraction buffer containing
protease inhibitors but lacking Triton X-100, and subsequently
incubated with anti-FEN-1 (25) or anti-WRN (H-300, Santa
Cruz Biotech.) antibodies for 6 h at 4C. Protein A–Sepharose
(50 ml) (Amersham Pharmacia Biotech) was added, and the
resulting mix was rotated at 4C for overnight. The beads were
then washed three times in Tris-buffered saline [50 mM Tris–
HCl (pH 8.0) and 150 mM NaCl] containing 0.1% Triton
X-100, and the immunoprecipitated proteins were eluted by
boiling with Laemmli sample buffer. Samples were electro-
phoresed on 10% SDS–PAGE, transferred to PVDF mem-
branes, and analyzed by western blot. WRN and FEN-1
were detected using mouse monoclonal anti-WRN (1:250,
Novus) and anti-FEN-1 (25) antibodies, respectively.
ELISA studies
Purified recombinant FEN-1 proteins (wild-type FEN-1,
FEN-1DP, FEN-1DC) were diluted to a concentration of
1 ng/ml in Carbonate buffer (0.016 M Na2CO3 and 0.034 M
NaHCO3, pH 9.6) and were added to appropriate wells of a
96-well microtiter plate (50 ml/well), which was incubated at
4C. BSA was used in the coating step for control reactions.
The samples were aspirated, and the wells were blocked for
2 h at 30C with Blocking buffer (PBS, 0.5% Tween 20 and
3% BSA). The procedure was repeated. WRN was diluted in
Blocking buffer, and the indicated concentrations were added
to the appropriate wells of the ELISA plate (50 ml/well), which
was incubated for 1 h at 30C. For ethidium bromide (EtBr)
treatment, 50 mg/ml EtBr was included in the incubation with
WRN during the binding step in the corresponding wells. The
samples were aspirated, and the wells were washed five times
before addition of anti-WRN antibody (H-300; Santa Cruz
Biotech.) that was diluted 1:500 in Blocking buffer. Wells
were then incubated at 30C for 1 h. Following three washings,
HRP-conjugated anti-rabbit secondary antibody (1:5000) was
added to the wells, and the samples were incubated for 30 min
at 30C. After washing five times, any WRN bound to the
immobilized FEN-1 was detected using OPD substrate
(Sigma). The reaction was terminated after 3 min with 3 N
H2SO4, and absorbance readings were taken at 490 nm. The
absorbance was corrected for the background signal in the
presence of BSA. The fraction of the immobilized FEN-1
bound to the microtiter well that was specifically bound by
WRN was determined from the ELISA assays. A Hill plot was
used to analyze the data as described previously (32).
Oligonucleotide substrates
PAGE-purified oligonucleotides (Midland Certified Reagent
Co., Midland, TX or Lofstrand Labs, Gaithersburg, MD) were
used for preparation of DNA substrates. The 26 nt 50 flap,
nicked duplex, and double flap with 1 nt 30 noncomplementary
tail substrates were prepared as described previously (24,33).
Electrophoretic mobility shift assays
The indicated concentrations of WRN (60, 120, 240 nM) and
FEN-1 or FEN-1DC (60, 120 nM) were incubated in Binding
buffer [50 mM Tris–HCl (pH 8.0), 10 mM NaCl, 5 mM EDTA,
10% glycerol and 50 mg/ml BSA] with 50 fmol double-flap
substrate in a total volume of 20 ml at 25C for 15 min.
Protein–DNA complexes were resolved on native 5% polyac-
rylamide 0.5· TBE gels, and visualized by phosphorimage
analysis.
FEN-1 incision assays
Reactions (20 ml) contained 10 fmol of the indicated DNA
substrate and the specified amounts of WRN, WRN949–1432,
BLM, FEN-1, FEN-1DP and/or FEN-1DC in 30 mM HEPES
(pH 7.6), 5% glycerol, 40 mM KCl, 0.1 mg/ml BSA, and 8 mM
MgCl2. WRN, WRN949–1432 or BLM was mixed with the
substrate and buffer on ice prior to the addition of FEN-1.
Reactions were incubated at 37C for 15 min and were ter-
minated by the addition of 10 ml of Formamide stop solution
[80% formamide (v/v), 0.1% bromophenol blue and 0.1%
xylene cyanol], and heated to 95C for 5 min. Products
were resolved on 20% polyacrylamide, 7 M urea denaturing
gels. A PhosphorImager was used for detection and Image-
Quant software (Molecular Dynamics) was used for quanti-
fication of the reaction products. Percent incision was
calculated as described previously (19). Cleavage data repres-
ent the mean of at least three independent experiments with
SDs shown by error bars.
RESULTS
WRN or BLM binding activity resides within a short
C-terminal region of FEN-1 adjacent to the PCNA
interacting domain
To map the WRN and BLM interaction sites on FEN-1, we
tested a series of GST fusion proteins that contain various
regions of human FEN-1 for WRN/BLM binding activity
using a pull-down affinity bead interaction assay (Figure 1).
WRN or BLM binding activity was contained entirely within
amino acids 363–380 of FEN-1. All fusion proteins that con-
tained this region bound WRN or BLM, whereas none of the
recombinant proteins tested that lacked the complete 18 amino
acid sequence displayed binding activity.
It was reported previously that PCNA interacts with FEN-1
by a conserved PCNA binding box motif residing within resi-
dues 328–355 of FEN-1 (30). In contrast, FEN-1 residues 363–
380 do not interact with PCNA (30). These results and our
current mapping data for WRN suggest that the PCNA and
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WRN interaction sites on FEN-1 reside adjacent to each other
in the C-terminal region of the FEN-1 protein. To address the
relative importance of the two C-terminal regions of FEN-1 in
mediating the WRN interaction, we tested two deletion mutant
forms of FEN-1, one lacking the PCNA binding region (resi-
dues 337–344, FEN-1DP) and the other lacking the WRN
binding region (residues 360–380, FEN-1DC) for interaction
with WRN by ELISA assay, and compared these results with
those obtained for the WRN interaction with full-length
FEN-1 (Figure 2). Deletion of residues 360–380 correspond-
ing to the WRN-interacting region of FEN-1 significantly
reduced the ability of WRN to bind to the immobilized
FEN-1. However, deletion of residues 337–344 corresponding
to the PCNA interacting region of FEN-1 did not hamper
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Figure 1. WRN or BLM binding activity of FEN-1 is contained within amino acids 363–380. (A) Schematic representation of GST-FEN-1 recombinant fragments
used for WRN pull-down experiments. (B) Amido black-stained membrane of protein complexes bound to glutathione–agarose beads in pull-down binding assay.
Beads were mixed with lysate from bacteria expressing GST fusion proteins containing human FEN-1 amino acids 254–380 (lane 1), 254–363 (lane 2), 254–328
(lane 3), 328–355 (lane 4), 328–380 (lane 5), 363–380 (lane 6), 328–363 (lane 7), GST alone (lane 8) or the agarose beads (lane 9). Purified recombinant WRN or BLM
proteins (200 ng) were added to the indicated affinity beads. After washing, protein complexes were eluted and analyzed by SDS–PAGE. Bound WRN (upper panel)
or BLM (lower panel) was detected by western blot analysis as described in Materials and Methods. Purified recombinant WRN or BLM protein (50 ng) was used as a
marker for western blot (lane 10). In other experiments, greater amounts of the fusion protein GST–FEN-1254–363 bound to glutathione beads that were more similar
to the other GST fusion proteins did not pull down WRN or BLM (data not shown).
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WRN binding to FEN-1. These results lead us to conclude that
WRN physically binds to the last 18 amino acids of the
C-terminal tail of FEN-1, and that the adjacent PCNA binding
domain of FEN-1 is not required for the physical interaction
of WRN with FEN-1.
WRN stimulates the nucleolytic activity of FEN-1
by physically interacting with its 360-380
C-terminal residues
Previously, we had demonstrated that the functional inter-
action between WRN and FEN-1 whereby WRN stimulates
the endonucleolytic and exonucleolytic functions of FEN-1 on
50 flap and nicked duplex DNA substrates is mediated by a
non-catalytic C-terminal domain of WRN that physically
interacts with FEN-1 (19). These results suggested (but did
not prove) that the physical protein interaction between WRN
and FEN-1 was required for the functional interaction. How-
ever, given the fact that C-terminal fragments of WRN that
harbor the RQC or HRDC domains bind DNA (34), it was
conceivable that the interaction of the WRN non-catalytic
domain with the DNA substrate might be solely responsible
for the stimulation of FEN-1 incision activities. To experi-
mentally address the importance of the physical interaction
between WRN and FEN-1 for the functional interaction, we
examined the ability of WRN to stimulate the cleavage activity
of the FEN-1 deletion mutant lacking the WRN-interacting
domain (FEN-1DC). The FEN-1DC recombinant protein was
shown to have reduced enzymatic activity; however, the
incision activity of FEN-1 DC could be stimulated by PCNA
(28). The results from FEN-1 incision assays demonstrate that
the cleavage activity of FEN-1DC lacking the WRN-
interacting region was not stimulated by WRN protein on a
26 nt 50 flap substrate (Figure 3A, lanes 6 and 7, and Figure 3C).
In control reactions, WRN stimulated the cleavage activity of
full-length FEN-1 by 7-fold (Figure 3A, lanes 2 and 3, and
Figure 3C), consistent with previous results (19,23). We also
tested the effect of WRN on the cleavage activity catalyzed by
the FEN-1DP and found that its cleavage activity was stimu-
lated similar to that observed for the full-length FEN-1
(Figure 3A and C). These results indicate that the WRN-
interacting region of FEN-1, but not the PCNA binding
domain of FEN-1, is required for WRN to stimulate FEN-1
endonucleolytic cleavage of the 50 flap substrate.
We next tested the ability of a non-catalytic WRN domain
fragment (WRN949–1432) that physically interacts with FEN-1
to stimulate the FEN-1DC and FEN-1DP recombinant pro-
teins. As observed for the full-length WRN protein,
WRN949–1432 failed to stimulate 5
0 flap cleavage by FEN-
1DC (Figure 3B, lanes 6 and 7, and Figure 3C), but retained
the ability to stimulate cleavage catalyzed by either full-length
FEN-1 (Figure 3B, lanes 2 and 3, and Figure 3C) or the FEN-
1DP (Figure 3B, lanes 4 and 5, and Figure 3C). Taken together
with the data from the FEN-1 incision assays with full-length
WRN, the results support those obtained from the physical
interaction mapping studies and provide evidence that the
direct binding of WRN to FEN-1 is responsible for the func-
tional interaction between the proteins.
In addition to its endonucleolytic activity, FEN-1 can func-
tion as an exonuclease on nicked duplex DNA substrates. To
address whether or not the WRN-interacting region of FEN-1
is important for the stimulatory effect of WRN on FEN-1
exonuclease activity, we examined incision activity of
FEN-1 and its deletion derivatives on a nicked duplex sub-
strate. The results from these studies, shown in Figure 4, dem-
onstrate that the exonuclease activity of FEN-1DC was not
affected by WRN whereas the presence of WRN stimulated
wild-type FEN-1 exonuclease activity on the nicked duplex as
expected. Similarly, WRN also retained the ability to stimulate
the exonuclease activity of FEN-1DP (data not shown).
WRN949–1432 also stimulated the exonuclease activity of
wild-type FEN-1 or FEN-1DP on the nicked duplex, but not
the exonuclease activity of FEN-1DC (data not shown). From
these results, we conclude that the WRN-interacting region of
FEN-1 is required in order for WRN to stimulate the FEN-1
exonuclease activity on nicked DNA duplex molecules.
Stimulation of FEN-1 cleavage by WRN in the
presence of PCNA
The physical and functional mapping results indicate that
WRN stimulates FEN-1 cleavage by its binding to the
C-terminal tail of FEN-1. Since the WRN interaction site
on FEN-1 resides adjacent to, but does not overlap with the
PCNA interaction site, we wanted to determine what effect the
combination of both WRN and PCNA in the FEN-1 incision
reaction might have. To examine the possibility that both
WRN and PCNA might retain their respective abilities to
stimulate FEN-1 cleavage in the presence of each other, we
used limiting amounts of the proteins such that an additive or
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Figure 2. Detection of WRN–FEN-1 complexes by ELISA. Wild-type FEN-1,
FEN-1DC or FEN-1DP was coated onto ELISA plates. Following blocking with
3% BSA, the wells were incubated with increasing concentrations of purified
recombinant WRN (0–50 nM) for 1 h at 30C, and bound WRN was detected by
ELISA using a rabbit polyclonal antibody against WRN followed by incubation
with secondary HRP-labeled antibodies and OPD substrate. Data points are the
mean of three independent experiments performed in duplicate with SDs
indicated by error bars.
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synergistic effect of both WRN and PCNA on FEN-1 incision
might be detected. Since FEN-1 stimulation by PCNA is a
diffusion-limited process that requires a large stoichiometric
excess of PCNA (35,36), we used 3600 fmol PCNA which
stimulated FEN-1 cleavage 3-fold (Figure 5A, lanes 2 and 4,
and Figure 5B). In contrast, WRN stimulates FEN-1 cleavage
significantly more effectively than PCNA (19); consequently,
only 80 fmol WRN was used, resulting in 5.7-fold stimulation
of FEN-1 cleavage (Figure 5A, lanes 2 and 3, and Figure 5B).
The combined presence of WRN and PCNA with FEN-1 res-
ulted in a maximal (12.7-fold) stimulation of FEN-1 cleavage
(Figure 5A, lane 5, and Figure 5B). These results suggest that
WRN and PCNA do not interfere with each other in their
ability to stimulate FEN-1 cleavage.
The C-terminal tail of FEN-1 is required for the
functional interaction with Bloom syndrome helicase
To address the importance of the physical interaction between
BLM and FEN-1 for the functional interaction, we examined
the ability of BLM to stimulate the cleavage activity of the
FEN-1 deletion mutant lacking the BLM-interacting domain
(FEN-1DC). The results from FEN-1 incision assays demon-
strate that the cleavage activity of FEN-1DC was not stimu-
lated by BLM protein on a 26 nt 50 flap substrate (Figure 6A,
lanes 6 and 7, and Figure 6B). In control reactions, BLM
stimulated the cleavage activity of full-length FEN-1 by 16-
fold (Figure 6A, lanes 2 and 3, and Figure 6B). We also tested
the effect of BLM on the cleavage activity catalyzed by FEN-
1DP, which lacks the PCNA interaction domain and found that
its cleavage activity was stimulated similar to that observed for
the wild-type FEN-1. These results indicate that the BLM-
interacting region of FEN-1, but not the PCNA binding
domain of FEN-1, is required for BLM to stimulate FEN-1
endonucleolytic cleavage of the 50 flap substrate.
WRN stimulates FEN-1 cleavage of its preferred
double-flap substrate by interacting with the FEN-1
C-terminal tail and facilitating FEN-1 binding
to the DNA structure
Recent evidence suggests that the physiological substrate of
FEN-1 during DNA replication is a double-flap structure with
equilibrating 30 and 50 single-stranded DNA tails that arises
Figure 3. WRN-interacting region of FEN-1 is required for WRN stimulation of FEN-1 endonucleolytic cleavage of 50 flap substrate. Reaction mixtures (20 ml)
containing 10 fmol of the 26 nt 50 flap substrate, the specified concentrations of wild-type FEN-1, FEN-1DC or FEN-1DP, and either WRN (A) or WRN949–1432 (B) as
indicated were incubated at 37C for 15 min under standard conditions as described in Materials and Methods. Products were resolved on 20% polyacrylamide
denaturing gels. Phosphorimages of typical gels are shown. For each gel: lane 1, no enzyme; lanes 2, 4 and 6 are wild-type FEN-1, FEN-1DP and FEN-1DC,
respectively; lanes 3, 5 and 7 are wild-type FEN-1, FEN-1DP and FEN-1DC, respectively, in the presence of WRN (A) or WRN949–1432 (B); lane 8, WRN (A) or
WRN949–1432 (B) alone. (C) Per cent incision (mean value of at least three independent experiments with SDs indicated by error bars). Quantitative data are shown for
incision reactions with FEN-1, FEN-1DP or FEN-1DC alone (open bars), in the presence of WRN (light gray bars) or in the presence of WRN949–1432 (gray bars).
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Figure 4. WRN-interacting region of FEN-1 is required for WRN stimulation of FEN-1 exonucleolytic cleavage of nicked duplex substrate. Reaction mixtures
(20 ml) containing 10 fmol of the nicked duplex DNA substrate, the specified concentrations of wild-type FEN-1 or FEN-1DC, and WRN as indicated were incubated
at 37C for 15 min under standard conditions as described in Materials and Methods. Products were resolved on 20% polyacrylamide denaturing gels.
(A) Phosphorimage of a typical gel is shown. Lane 1, no enzyme; lanes 2 and 4 are wild-type FEN-1 and FEN-1DC, respectively; lanes 3 and 5 are wild-type
FEN-1 and FEN-1DC, respectively, in the presence of WRN. (B) Per cent incision (mean value of at least three independent experiments with SD indicated by error
bars). Quantitative data are shown for incision reactions with FEN-1 or FEN-1DC alone (open bars) or in the presence of WRN (light gray bars).
Figure 5. Combined effect of WRN and PCNA on stimulation of FEN-1 cleavage. Reaction mixtures (20 ml) containing 10 fmol of the 26 nt 50 flap substrate and the
indicated concentrations of FEN-1, WRN and/or PCNA were incubated at 37C for 15 min under standard conditions as described in Materials and Methods. Products
were resolved on 20% polyacrylamide denaturing gels. (A) Phosphorimage of a typical gel is shown. Lane 1, no enzyme; lane 2, FEN-1; lane 3, FEN-1 + WRN;
lane 4, FEN-1 + PCNA; lane 5, FEN-1 + WRN + PCNA; lane 6, WRN + PCNA; lane 7, WRN; lane 8, PCNA. (B) Per cent incision (mean value of at least three
independent experiments with SD indicated by error bars).
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after strand displacement DNA synthesis catalyzed by a DNA
polymerase (37,38). FEN-1 preferentially cleaves the double-
flap substrate with a 1 nt 30 tail at a precise position 1 nt into the
downstream annealed region, allowing the 30 tail to anneal and
generate a nick suitable for ligation. Because the double flap
was proposed to be the cellular substrate of FEN-1, and in vivo
evidence suggests that WRN has a role in DNA replication by
its interaction with FEN-1, we investigated the mechanism
for WRN stimulation of FEN-1 cleavage of the double-flap
structure. The results in Figure 7 show that WRN stimulated
wild-type FEN-1 cleavage of the double-flap substrate by
6.5-fold, whereas no stimulatory effect by WRN was observed
for the FEN-1DC enzyme. Thus, as observed for the fixed 50
flap substrate, the ability of WRN to stimulate FEN-1 cleavage
of the double-flap substrate was dependent on the presence
of the C-terminal region of FEN-1 that interacts with WRN.
We also observed that the WRN949–1432 fragment was unable
to stimulate FEN-1DC, but retained the ability to enhance
cleavage of the double flap by wild-type FEN-1 (data not
shown).
The previously published data indicated that the C-terminal
tail of FEN-1 with which WRN or BLM helicases interact
plays a role in DNA binding (28). These observations sugges-
ted to us that WRN may affect FEN-1 binding to its DNA
substrate through its interaction with the C-terminal region of
FEN-1. To experimentally address this hypothesis, we tested
the effect of WRN on FEN-1 binding to the double-flap
substrate using either the wild-type FEN-1 or FEN-1DC. As
shown by gel-shift analysis, a significantly greater amount of
the double-flap substrate was bound at 120 nM FEN-1 com-
pared with 60 nM FEN-1 (Figure 7C, lane 6 versus 2). The
presence of WRN in the FEN-1 binding mixtures enhanced the
amount of the shifted FEN-1:DNA species (Figure 7C, lanes
3–5). WRN alone did not shift the double-flap substrate
(Figure 7C, lanes 7–9) to the position of the FEN-1:DNA
complex. We next examined the effect of WRN on the ability
of FEN-1DC to bind the double flap. As shown in Figure 7D,
WRN did not improve FEN-1DC binding to the substrate at
WRN protein concentrations in which wild-type FEN-1 bind-
ing to the double flap was effectively enhanced. These results
indicate that WRN helps FEN-1 bind to its preferred double-
flap substrate and that the C-terminal tail of FEN-1 that
physically binds to WRN is necessary not only for WRN to
stimulate FEN-1 cleavage of the double flap but also WRN
enhancement of FEN-1 binding to the structure.
WRN retains the ability to stimulate acetylated FEN-1
It was reported recently that FEN-1 can be acetylated by p300
and that acetylation down-regulates FEN-1 incision activity
(26). Three of the four acetylated lysine residues of FEN-1
were mapped to the extreme C-terminus which overlaps with
the WRN binding site of FEN-1 (26). To assess the importance
of FEN-1 acetylation status for the WRN–FEN-1 functional
interaction, we examined the ability of WRN protein to stimu-
late acetylated FEN-1 in vitro. Under conditions in which
FEN-1 is acetylated by p300 (Figure 8A), the FEN-1 cleavage
reaction on the 26 nt 50 flap substrate is significantly reduced
(Figure 8B), consistent with earlier observations that FEN-1
cleavage activity on a 20 nt 50 flap structure is reduced6-fold
by FEN-1 acetylation (26). As shown in Figure 8B, WRN
retains the ability to stimulate acetylated FEN-1. From quant-
itative analysis of the FEN-1 incision data it was determined
that WRN (100 fmol) stimulated acetylated FEN-1 cleavage
was from 5 to 43% at 40 fmol FEN-1 (Figure 8C). The 8.5-fold
increase in cleavage activity by acetylated FEN-1 in the
presence of WRN is very comparable with the fold stimulation
of incision by unacetylated FEN-1 when WRN is present
(Figure 3). To assess if FEN-1 acetylation modulates its ability
to bind WRN, we performed ELISA assays with unacetylated
or acetylated FEN-1 and WRN. The results, shown in
Figure 8D, demonstrate that WRN retains its ability to
physically interact with FEN-1 in its acetylated form similar
Figure 6. BLM-interacting region of FEN-1 is required for BLM stimulation of
FEN-1 endonucleolytic cleavage of 50 flap substrate. Reaction mixtures (20 ml)
containing 10 fmol of the 26 nt 50 flap substrate, the specified concentrations of
wild-type FEN-1, FEN-1DC or FEN-1DP, and BLM were incubated at 37C for
15 min under standard conditions as described in Materials and Methods.
Products were resolved on 20% polyacrylamide denaturing gels. (A) Phosphor-
image of a typical gel is shown. Lane 1, no enzyme; lanes 2, 4 and 6 are wild-
type FEN-1, FEN-1DP and FEN-1DC, respectively; lanes 3, 5 and 7 are
wild-type FEN-1, FEN-1DP and FEN-1DC, respectively, in the presence of
BLM; lane 8, BLM alone. (B) Per cent incision (mean value of at least three
independent experiments with SD indicated by error bars). Quantitative data
are shown for incision reactions with FEN-1 or FEN-1DC alone (open bars) or
in the presence of BLM (light gray bars).
6776 Nucleic Acids Research, 2005, Vol. 33, No. 21
Figure 7. WRN facilitates FEN-1 binding to the double-flap DNA substrate through its interaction with the C-terminal tail of FEN-1. (A and B) Reaction mixtures (20
ml) containing 10 fmol of the double flap DNA substrate, the specified concentrations of wild-type FEN-1 or FEN-1DC, and WRN as indicated were incubated at 37C
for 15 min under standard conditions as described in Materials and Methods. Products were resolved on 20% polyacrylamide denaturing gels. (A) Phosphorimage of a
typical gel is shown. Lane 1, no enzyme; lanes 2 and 4 are wild-type FEN-1 and FEN-1DC, respectively; lanes 3 and 5 are wild-type FEN-1 and FEN-1DC,
respectively, in the presence of WRN. (B) Per cent incision (mean value of at least three independent experiments with SDs indicated by error bars). Quantitative
data are shown for incision reactions with FEN-1 or FEN-1DC alone (open bars) or in the presence of WRN (light gray bars). (C and D) Binding mixtures
(20 ml) containing 10 fmol of the double flap DNA substrate, the specified concentrations of wild-type FEN-1 (C) or FEN-1DC (D), and WRN as indicated were
incubated at 37C for 15 min as described in Materials and Methods. Products were resolved on native 5% polyacrylamide gels. Phosphorimages of typical gels are
shown.
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to that observed with unacetylated FEN-1. From the physical
and functional assays, we can conclude that FEN-1 acetylation
does not interfere with the ability of FEN-1 to interact
with WRN.
The ability of WRN to physically and functionally interact
with acetylated FEN-1 suggested that the lysine residues in the
WRN-interacting region of FEN-1 that have been shown to be
acetylated (26) may not be critical for the WRN interaction. To
Figure 8. WRN retains the ability to physically bind and stimulate acetylated FEN-1. (A) Purified recombinant FEN-1 was acetylated in vitro by incubating with
p300-HAT and [14C]acetyl coenzyme A (AcCoA) as described in Materials and Methods and resolved on SDS denaturing 10% polyacrylamide gel. The gel was
exposed to X-ray film and developed by autoradiography (upper panel) or stained with Coomassie (lower panel). (B) Reaction mixtures (20ml) containing 10 fmol of
the 26 nt 50 flap substrate, acetylated or unacetylated FEN-1 (0.625, 1.25, 2.5, 5, 10, 20 and 40 fmol) and WRN (100 fmol) were incubated at 37C for 15 min under
standard conditions as described in Materials and Methods. Products were resolved on 20% polyacrylamide denaturing gels. A phosphorimage of a typical gel is
shown. Lanes 16 and 17 show the products of cleavage reactions containing 0.625 fmol FEN-1 (with AcCoA but lacking p300) in the absence and presence of WRN,
respectively. (C) Per cent incision (mean value of at least three independent experiments with SD indicated by error bars from experiments as conducted in (B).
Quantitative data are shown for incision reactions with acetylated FEN-1 alone (open bars) or in the presence of WRN (light gray bars). (D) FEN-1 that had been
preincubated with or without p300-HAT and/or AcCoA as indicated was coated onto ELISA plates. Following blocking with 3% BSA, the wells were incubated with
increasing concentrations of purified recombinant WRN (0–50 nM) for 1 h at 30C, and bound WRN was detected by ELISA using a rabbit polyclonal antibody
against WRN followed by incubation with secondary HRP-labeled antibodies and OPD substrate. Data points are the mean of three independent experiments
performed in duplicate with SDs indicated by error bars.
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explore this further, we performed WRN binding assays with
FEN-1 mutant proteins in which one or more of the C-terminal
lysine residues shown to be acetylated by p300 were replaced
with alanines (39). The results from ELISA assays, shown in
Supplementary Figure 1, demonstrate that WRN physically
binds to each of the FEN-1 lysine mutants similarly, and in
a comparable fashion to wild-type FEN-1. From a Hill plot
analysis of the ELISA data, it was determined that the apparent
dissociation constant (Kd) values for the WRN interaction with
the various FEN-1 lysine mutants are all similar to that repor-
ted for the interaction of wild-type FEN-1 with WRN (23).
Collectively, the results indicate that the lysine residues in the
C-terminus of FEN-1 do not play a critical role in the WRN
interaction.
Increased association of WRN and FEN-1 in the
chromatin fraction after DNA damage
The replication defects and sensitivity of WS cells to DNA
damaging agents that introduce replication fork blocking
lesions suggest a specialized role of WRN at stalled replication
forks. Consistent with this idea, WRN cellular localization
studies have shown that WRN exits nucleoli in response to
various DNA damaging agents and co-localizes with several
proteins including FEN-1, RPA, PCNA and RAD52 at arrested
replication foci [for review see (17,18)]. The earlier observa-
tions that FEN-1 is localized to repair foci after DNA damage
(40) and becomes closely associated with WRN at arrested
replication forks (24) suggested that the two proteins would be
associated with each other in the same subnuclear fraction
after treatment of cells with the interstrand cross-linking
agent mitomycin C (MMC) that blocks replication fork pro-
gression. Detergent extracted lysates from untreated or MMC-
treated cells were separated into soluble, high salt or chromatin
fractions and analyzed for the presence of WRN or FEN-1 by
western blotting. The results from a representative experiment
in Figure 9A show that a greater amount of both WRN and
FEN-1 are found in the high salt and chromatin fractions upon
MMC treatment. The amount of WRN or FEN-1 found in the
chromatin fraction was dependent on the concentration of
MMC in the cellular treatment (Figure 9B). To control for
loading, the same blot was probed with antibody against
Histone H4 (Figure 9B, lower panel). We next performed
WRN–FEN-1 co-immunoprecipitation experiments using an
antibody directed against FEN-1 and either the chromatin or
soluble fractions. As we showed previously (19), WRN and
FEN-1 were co-immunoprecipitated from the soluble fraction.
As shown in Supplementary Figure 2, WRN and FEN-1 were
associated with each other in the chromatin fraction and an
increased amount of WRN was associated with FEN-1 in the
chromatin fraction of MMC-treated cells compared with the
untreated cells. Taken together, these results and WRN–FEN-
1 FRET analyses (24) suggest that WRN and FEN-1 become
associated with each other in the chromatin fraction at arrested
replication foci.
DISCUSSION
Mutations in the WRN or BLM helicases are associated with a
number of replication defects that include impaired fork pro-
gression, accumulation of abnormal replication intermediates
and aberrant homologous recombination [for a review see
(41)]. The results from biochemical and biological studies
suggest that the cellular interaction between WRN and
FEN-1 is important when DNA processing events during rep-
lication are compromised. By mapping the interaction site on
FEN-1 for WRN or BLM, we have gained further understand-
ing to how the involvement of FEN-1 with either WRN or
BLM might be coordinated with its associations with other
DNA replication/repair proteins including PCNA. The fact
that the WRN/BLM interaction site is immediately adjacent
to the PCNA binding site suggests that the C-terminal tail of
FEN-1 is a major site for the regulation of its catalytic activity
through its protein partner interactions. The shared FEN-1
binding site for WRN and BLM suggests that the two
RecQ helicases are probable to modulate FEN-1 incision by
a similar mechanism. The precise temporal and spatial aspects
of how WRN, BLM and PCNA coordinate their interactions
with FEN-1 during the dynamic processes of DNA replication
or repair remain to be fully understood. Nevertheless, the
mapping studies show that it is possible for FEN-1 to interact
with PCNA and WRN (or BLM) either separately or simul-
taneously to perform its functions.
Figure 9. Enriched association of WRN–FEN-1 in the chromatin fraction after DNA damage. (A) Greater fraction of WRN and FEN-1 is found in the chromatin
fraction after exposure of cells to MMC. Subnuclear fractionation was performed as described in Materials and Methods. Western blot detection of WRN and FEN-1
in different subnuclear fractions of HeLa cells treated with or without MMC (0.5 mg/ml). (B) Enrichment of WRN and FEN-1 in the chromatin fraction is dependent
on MMC dose. Western blot detection of WRN and FEN-1 in the chromatin fractions prepared from HeLa cells treated with or without 0.25, 0.5 or 1 mg/ml MMC.
Bottom panel shows Histone H4 detected by western blot.
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Our previous studies to investigate the kinetic mechanism for
WRN stimulation of FEN-1 cleavage demonstrated that the
mechanism whereby WRN stimulates FEN-1 cleavage (42)
is distinct from that proposed for the functional interaction
between PCNA and FEN-1 (43). Since PCNA was shown to
not interact with the WRN binding site (residues 363–380) (30),
and WRN was shown in this study to not interact with the PCNA
binding site (residues 328–355), the mapping results clearly
indicate distinct binding sites for WRN and PCNA on FEN-
1. The distinction between WRN and PCNA for their FEN-1
interaction sites is probable to be important for their respective
mechanisms of action with FEN-1 during DNA processing.
PCNA is required for the structural integrity of the replica-
tion fork and its normal progression during DNA synthesis of
the replicating chromosome. One possibility is that WRN or
BLM may be utilized as substitutes for PCNA in their inter-
action with FEN-1 at sites of DNA damage repair. Alternat-
ively, PCNA may collaborate with WRN (or BLM) to
stimulate FEN-1 cleavage, as suggested by the in vitro studies
in this work. The disruption of the FEN-1–PCNA interaction
by competitive binding of p21 to the FEN-1 interaction site of
PCNA (44) may serve to enable WRN or BLM to interact with
FEN-1 when normal replication fork progression is perturbed.
In contrast to PCNA, WRN and BLM share the same FEN-1
interaction site. This discovery coupled with the fact that
WRN and BLM interact with FEN-1 through a conserved
non-catalytic region that resides C-terminal to the RecQ hel-
icase core domain suggests a conserved protein interaction
interface of WRN and BLM with FEN-1. The crystal structure
of the conserved catalytic core of the E.coli RecQ helicase
revealed that it comprises four independently folded structural
subdomains: two of them form the helicase region and the
two RQC subdomains constitute a Zn2+ binding domain and
winged helix (45). Interestingly, the winged helix sub-domain
aligns with the first 110 residues of the FEN-1 interaction
domain of WRN (WRN949–1092) as well as a segment of the
BLM domain fragment (residues 1076–1217) that mediates
the FEN-1 interaction. This suggests that the FEN-1 interac-
tion domain of WRN or BLM protein folds independently
from other regions of the protein and may be capable of func-
tioning independently. Consistent with this notion, WRN or
BLM fragments harboring the FEN-1 interaction domain are
able to bind the minimal FEN-1 sequence, residues 363–380,
that mediates the interaction of FEN-1 with full-length WRN
or BLM proteins.
What factors might be important in regulating the interac-
tion of FEN-1 with its protein partners and how might this be
important in vivo? In human cells, the post-translational modi-
fication state of FEN-1 or its interacting partner may regulate
its role in replication or cell cycle progression. Acetylation of
FEN-1 by the transcriptional coactivator p300 is enhanced
upon UV treatment of human cells, and significantly reduces
FEN-1’s DNA binding and nuclease activity (26). Three of the
four identified acetylated lysine residues were located in the
extreme C-terminal tail of FEN-1 that is the binding site for
WRN. Despite the fact that FEN-1 is acetylated in the WRN
binding site, the acetylated form of FEN-1 can be optimally
stimulated by WRN.
It was proposed that the unique C-terminal region of FEN-1
might be important to regulate its enzymatic activity through
modulation of DNA substrate binding. This hypothesis is
supported by the demonstration that WRN enhances FEN-1
binding to its preferred double-flap DNA substrate. The C-
terminal region of FEN-1 is not present in prokaryotic organ-
isms (Archaea), suggesting a specialized function in DNA
metabolism. The unique C-terminal tail of FEN-1 is an import-
ant site for binding of WRN or BLM helicases, and the absence
of the tailored interaction may contribute to the genomic
instability of WS and Bloom syndrome.
The results from the WRN/BLM-FEN-1 mapping studies
may have some bearing on understanding the impact of genetic
mutations on human disease. Single nucleotide polymorph-
isms in FEN-1 have been identified in the human population
(http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusld=2237
&chooseRs=all), including a Phe/Leu variation at residue 376
in the C-terminal tail of FEN-1 where BLM or WRN proteins
interact with FEN-1 (refSNP number rs7931165). Biochem-
ical and genetic characterization of the 376 variants and other
FEN-1 polymorphic variants will be informative as their
importance in human disease is assessed. In addition, two
of the known BLM clinical missense mutations (46,47) reside
in the RecQ-Ct region that is responsible for the FEN-1 phys-
ical and functional interaction (25). Future work will address
the importance of genetic variations that impact the interac-
tions of RecQ helicases with Rad2 nucleases.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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